Stockscreener 앱 받기
35.59
0.17%
0.06
시장 영업 전:
35.64
0.05
+0.14%
전일 마감가:
$35.53
열려 있는:
$35.88
하루 거래량:
164.33K
Relative Volume:
0.50
시가총액:
$1.70B
수익:
-
순이익/손실:
$-111.48M
주가수익비율:
-12.42
EPS:
-2.865
순현금흐름:
$-88.09M
1주 성능:
+5.48%
1개월 성능:
+5.99%
6개월 성능:
+36.00%
1년 성능:
+224.13%
1일 변동 폭
$34.84
$36.65
1주일 범위
$32.41
$36.65
52주 변동 폭
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
명칭
Rapport Therapeutics Inc
전화
857-321-8020
주소
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
35.59 | 1.70B | 0 | -111.48M | -88.09M | -2.865 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Strong Buy |
| 2026-02-02 | 개시 | Wells Fargo | Overweight |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-09-16 | 개시 | Truist | Buy |
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-04-08 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 개시 | Jefferies | Buy |
| 2024-07-02 | 개시 | Stifel | Buy |
| 2024-07-02 | 개시 | TD Cowen | Buy |
모두보기
Rapport Therapeutics Inc 주식(RAPP)의 최신 뉴스
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings - Yahoo Finance
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Third Rock Ventures Sells 17 Million Dollars in Rapport Therapeutics - HarianBasis.co
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near - AOL.com
Bullish Rapport Therapeutics Insiders Loaded Up On US$1.61m Of Stock - 富途牛牛
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily
Rapport Therapeutics prices $250M stock at $26 per share - MSN
RAPP Should I Buy - Intellectia AI
Rapport Therapeutics, Inc. ($RAPP) CEO 2025 Pay Revealed - Quiver Quantitative
BTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), Danaher (DHR) and Intuitive Surgical (ISRG) - The Globe and Mail
Rapport Therapeutics (RAPP) outlines 2026 vote, board structure and executive pay - Stock Titan
Rapport Therapeutics Reports Sustained Seizure Reduction With RAP-219 in Phase 2a Focal Onset Seizure Trial at 2026 AAN Meeting - Minichart
Rapport Therapeutics advances RAP-219 after strong Phase 2a data - The Globe and Mail
Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Rapport Therapeutics CDO Yeleswaram Krishnaswamy sells $808,844 stock By Investing.com - Investing.com India
Third Rock Ventures sells $17.1m in Rapport Therapeutics stock - Investing.com UK
Rapport Therapeutics reports extended efficacy data for RAP-219 By Investing.com - Investing.com Australia
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Th - GuruFocus
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells 426,005 Shares of Stock - MarketBeat
Third Rock Ventures sells $17.1m in Rapport Therapeutics stock By Investing.com - Investing.com South Africa
RAPP Reports Positive Results from Phase 2a Trial Follow-Up - GuruFocus
Krishnaswamy Yeleswaram Sells 20,225 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics Presents Rap-219 Focal Onset Seizure Phase 2A Follow-Up Period Results - TradingView
Rapport Therapeutics CDO Yeleswaram Krishnaswamy sells $808,844 stock - Investing.com
Rapport Therapeutics reports extended efficacy data for RAP-219 - Investing.com
Rapport Therapeutics reports sustained seizure reductions, 22-day half-life for RAP-219 in Phase 2a follow-up - TradingView
Rapport Therapeutics (RAPP) posts durable RAP-219 seizure cuts and details late-stage plans - Stock Titan
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting - The Manila Times
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.2%Here's What Happened - MarketBeat
Rapport Therapeutics (RAPP) Stock Value Opportunity (On the Radar) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Is Rapport Therapeutics (RAPP) stock continuing its trend (Ticks Higher) 2026-04-18Public Sentiment - Xã Châu Thành
Rapport Therapeutics (NASDAQ:RAPP) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Brokered 10b5-1 sales listed for RAPP (NASDAQ: RAPP) - Stock Titan
[144] Rapport Therapeutics, Inc. SEC Filing - Stock Titan
(RAPP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 9,165 Shares of Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 500 Shares - MarketBeat
Rapport Therapeutics Insider Sold Shares Worth $695,823, According to a Recent SEC Filing - marketscreener.com
Rapport Therapeutics (RAPP) CDO sells 19,865 shares under 10b5-1 plan - Stock Titan
10b5-1 insider sales reported for RAPP (NASDAQ: RAPP) in March–April 2026 - Stock Titan
What is the dividend outlook for Rapport Therapeutics (RAPP) Stock | Price at $34.13, Down 0.12%Expert Entry Points - Newser
Is Rapport Therapeutics Inc undervalued by DCF analysis2026 Pullbacks & Reliable Price Breakout Alerts - baoquankhu1.vn
How Investors May Respond To Rapport Therapeutics (RAPP) Phase 2a RAP-219 Data Spotlight At AAN 2026 - simplywall.st
Rapport Therapeutics Inc (RAPP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rapport Therapeutics Inc 주식 (RAPP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Yeleswaram Krishnaswamy | Chief Development Officer |
Apr 17 '26 |
Sale |
39.99 |
20,225 |
808,844 |
246,426 |
0.14%
0.48%
자본화:
|
볼륨(24시간):